NCT07219576 (PRISM) is a Phase 1/Phase 2 clinical trial of Ruxolitinib in Non Small Cell Lung Carcinoma, sponsored by University of California, San Diego.

Who is sponsoring NCT07219576?

NCT07219576 is sponsored by University of California, San Diego.

What drugs are being tested in NCT07219576?

Interventions in NCT07219576: Ruxolitinib, Retifanlimab.

What condition does NCT07219576 study?

NCT07219576 studies Non Small Cell Lung Carcinoma, Renal Cell Carcinoma.

Is NCT07219576 still recruiting?

NCT07219576 is currently recruiting now. Last updated 10 January 2026.

Last reviewed 2026-01-10 · How we verify

NCT07219576: PRISM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition

Recruiting now Phase 1/Phase 2 Last updated 10 January 2026

What this trial tests

Phase 1/Phase 2 trial testing Ruxolitinib in Non Small Cell Lung Carcinoma in 40 participants. Currently enrolling.

Timeline

8 January 2026

Primary endpoint
1 December 2027

1 December 2029

Quick facts

Lead sponsor	University of California, San Diego
Phase	Phase 1/Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	8 January 2026
Primary completion	1 December 2027
Estimated completion	1 December 2029
Sites	1 location across United States

Drugs / interventions tested

Ruxolitinib (RUXOLITINIB) — full drug profile →
Retifanlimab (RETIFANLIMAB) — full drug profile →

Conditions studied

Non Small Cell Lung Carcinoma — all drugs for Non Small Cell Lung Carcinoma →
Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →

Sponsor

University of California, San Diego

Who can join

Eligibility, any sex, with Non Small Cell Lung Carcinoma or Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Recommended phase 2 dose
Time frame: 28 days
Determine the recommended phase 2 dose of ruxolitinib in combination with a fixed dose of retifanlimab. The recommended phase 2 dose will be determined by assessment of the dose limiting toxicities during the first cycle of treatment.

Sponsor's own description

The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma. The main question it aims to answer is: What is the maximum dose of ruxolitinib that can be used safely in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma, and will it work? Participants will: Take drug ruxolitinib twice a day and keep a diary of when they take ruxolitinib at home; visit the clinic for infusions of retifanlimab every 4 weeks; visit the clinic for checkups and tests.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

STAT3 at the tumor-immune interface: mechanisms of immune escape and therapeutic opportunities
Cheng X, Jing H, Zhang M. ·

Verify or expand the search:

Other trials of Ruxolitinib

Trials testing the same drug.

NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
NCT07311746 — Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07340138 — Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis · Phase 1 · not yet recruiting
NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting

Other University of California, San Diego trials

Trials by the same sponsor.

NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07219576 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 10 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07219576.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing